Healthcare
StageZero Life Sciences Ltd.(SZLSF)
Live Price
Offline$0.0051
+0.00% today
1Y Change
-82.22%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- โ
- Revenue Growth
- -25.1%
- EPS Growth
- -10.0%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
StageZero Life Sciences Ltd. (SZLSF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 82.2% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of -25.1%, EPS growth of -10.0%, a dividend yield of 0.0%. What stands out right now is revenue -25.1%, EPS -10.0%, free cash flow +61.2% with operating margin -204.1% and ROIC 151.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SZLSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-25.1% vs +7.6% peer median
Operating Margin
Below sector median
-204.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 25, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -25.1% and EPS is at -10.0%, with operating margin around -204.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 25, 2026 | โ | +0.0% | โ | โ |
2025 Dec 29, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 28, 2025 | โ | +0.0% | +0.0% | -56.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SZLSF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SZLSF Max Drawdown
-98.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SZLSF and SPY.
Company Overview
StageZero Life Sciences Ltd.
Other OTC
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
- Leadership
- James R. Howard-Tripp
- IPO Date
- Sep 8, 2009
- Employees
- 40
- Street Address
- 70 East Beaver Creek Road
- Mailing
- Richmond Hill, ON, L4B 3B2
- Region
- Richmond Hill, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 804 261 3340
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.2
- Price/Book
- โ
Growth
- Revenue
- -25.1%
- EPS
- -10.0%
- Free Cash Flow
- +61.2%
Profitability
- Gross Margin
- -10.6%
- Operating Margin
- -204.1%
- Net Margin
- -300.8%
- ROE
- 481.5%
- ROIC
- 151.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.